Placing and Subscription to raise approx £1.4m

AI SummaryClose X

Fusion Antibodies plc has successfully raised approximately £1.4 million before expenses through a placing and subscription of 11,056,905 new ordinary shares at 13 pence per share. This capital raise, which includes a £19,861.92 subscription by Non-Executive Director Colin Walsh, will be used to accelerate the commercialisation of its OptiMAL® platform, invest in strategic partnerships, fund global marketing efforts, and strengthen proprietary technologies. The company also announced the proposed issuance of 308,720 new ordinary shares to certain executive directors in satisfaction of a portion of their bonuses. Admission of the new shares to trading on AIM is anticipated on January 30, 2026.

Disclaimer*

UK 100

Latest directors dealings